3 Promising Penny Stocks With At Least $200M Market Cap

As the S&P 500 and Nasdaq Composite reach record highs, driven by optimism around potential interest rate cuts, investors are increasingly exploring diverse avenues for growth. Penny stocks, a term that traditionally refers to low-priced shares of smaller or newer companies, remain an intriguing segment of the market due to their potential for significant returns when backed by solid financials. In this article, we'll examine three penny stocks that demonstrate strong financial health and offer promising opportunities for those interested in under-the-radar investments with long-term potential.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.88 $669.08M ★★★★★★ WM Technology (MAPS) $1.13 $204.42M ★★★★★★ Puma Biotechnology (PBYI) $4.87 $245.31M ★★★★★★ Performance Shipping (PSHG) $1.84 $22.88M ★★★★★★ Tuniu (TOUR) $0.9326 $88.89M ★★★★★★ CI&T (CINT) $4.96 $696.85M ★★★★★☆ BAB (BABB) $0.904375 $6.46M ★★★★★★ Lifetime Brands (LCUT) $4.08 $82.7M ★★★★★☆ Resources Connection (RGP) $4.55 $149.03M ★★★★★★ TETRA Technologies (TTI) $3.97 $522.46M ★★★★★★

Click here to see the full list of 411 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Maravai LifeSciences Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Maravai LifeSciences Holdings, Inc. is a life sciences company that offers products supporting the development of drug therapies, vaccines, cell and gene therapies, and diagnostics across various global regions with a market cap of $524.60 million.

Operations: Maravai LifeSciences Holdings, Inc. has not reported specific revenue segments.

Market Cap: $524.6M

Maravai LifeSciences Holdings, Inc. has experienced significant challenges recently, with a net loss of US$39.59 million in Q2 2025 and a goodwill impairment charge of US$30.45 million. The company's short-term assets exceed both its long-term and short-term liabilities, providing some financial stability despite ongoing unprofitability and high volatility in share price. Recent executive changes aim to drive strategic growth and profitability, but the suspension of revenue guidance for 2025 reflects uncertainty amid leadership transitions. Despite these hurdles, Maravai's debt-to-equity ratio has improved significantly over five years, indicating progress in managing financial leverage effectively.

Jump into the full analysis health report here for a deeper understanding of Maravai LifeSciences Holdings. Assess Maravai LifeSciences Holdings' future earnings estimates with our detailed growth reports.

Story Continues

MRVI Revenue & Expenses Breakdown as at Aug 2025

3D Systems

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: 3D Systems Corporation offers 3D printing and digital manufacturing solutions across various regions worldwide, with a market cap of approximately $225.72 million.

Operations: The company has not reported any specific revenue segments.

Market Cap: $225.72M

3D Systems Corporation, with a market cap of US$225.72 million, recently reported Q2 2025 earnings showing revenue of US$94.84 million and net income of US$104.44 million, reversing a prior year's loss. However, the company remains unprofitable overall and faces high share price volatility. Despite this, its short-term assets significantly exceed liabilities, providing some financial cushion. The introduction of innovative products like the NextDent Jetted Denture Solution and FDA-approved bioprinting technologies highlights potential growth avenues amidst legal challenges from a class action lawsuit alleging misleading statements about business operations and financial health during challenging industry conditions.

Get an in-depth perspective on 3D Systems' performance by reading our balance sheet health report here. Review our growth performance report to gain insights into 3D Systems' future.DDD Revenue & Expenses Breakdown as at Aug 2025

SelectQuote

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: SelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform for selling insurance policies and healthcare services in the United States, with a market cap of approximately $331.62 million.

Operations: The company's revenue is primarily derived from its Senior segment at $632.07 million, Healthcare Services at $673.90 million, and Life insurance at $167.07 million.

Market Cap: $331.62M

SelectQuote, Inc., with a market cap of US$331.62 million, operates in the insurance and healthcare services sector. It faces challenges due to a securities class action lawsuit alleging misleading business practices, which could impact its reputation and legal standing. Despite being unprofitable, SelectQuote has a robust cash runway exceeding three years due to positive free cash flow growth. Its short-term assets cover liabilities but not long-term debt. Recent strategic initiatives include expanding its SelectRx service to improve medication adherence among Medicare beneficiaries, demonstrating commitment to enhancing health outcomes and potentially bolstering future revenue streams amidst ongoing legal issues.

Click here and access our complete financial health analysis report to understand the dynamics of SelectQuote. Examine SelectQuote's earnings growth report to understand how analysts expect it to perform.SLQT Revenue & Expenses Breakdown as at Aug 2025

Next Steps

Click here to access our complete index of 411 US Penny Stocks. Curious About Other Options? The end of cancer? These 26 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MRVIDDD and SLQT.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments